Original Study| Volume 14, ISSUE 4, e321-e327, August 2016

Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up

Published:November 17, 2015DOI:



      To investigate the functional and oncologic outcomes of patients with locally advanced or lymph node (LN) metastatic prostate cancer (PCa) treated by laparoscopic radical prostatectomy (LRP) with extended lymph node dissection (ePLND).


      From June 2004 to March 2014, a total of 232 cases (pT3-4N0-1M0) including 160 locally advanced PCa and 72 LN metastatic PCa who received immediate androgen deprivation therapy after LRP plus ePLND were enrolled onto our study. The patients were followed up for 12 to 124 months. Surgical records, surgical margin status, complications, urinary continence, and oncologic outcomes were presented.


      The mean operation time and bleeding were 230 minutes and 105 mL, respectively. The rates of urinary continence were 91.4% and 94.8% at 6 and 12 months, respectively. We observed 122 biochemical recurrent cases. The 5- and 8-year biochemical relapse-free survival rates were 47.3% and 46.7%, respectively. The 5- and 8-year overall and cancer-specific survivals were 81.2%, 80.1%, 90.6%, and 90.6%, respectively. The survival analysis showed that biochemical recurrence-free survival rates were significantly lower for patients with higher Gleason score (77.3% vs. 39.6% vs. 30.8%, P = .003 log rank), higher T stage (55.7% vs. 41.4% vs. 21.4%, P = .039 log rank), positive surgical margin (51.1% vs. 29.3%, P = .000 log rank), and higher CAPRA-S score (68.6% vs. 35.0% vs. 29.2%, P = .000 log rank). There were no significant differences in biochemical relapse-free (40.9% vs. 49.3%, P = .286), overall (75.6% vs. 81.9%, P = .398), and cancer-specific (87.3% vs. 92.1%, P = .284) survival between LN-positive and -negative PCa.


      LRP plus ePLND in combination with immediate androgen deprivation therapy is a feasible approach to patients with pT3-4N0-1M0 PCa; favorable functional and oncologic outcomes were presented postoperatively.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Denham J.W.
        • Steigler A.
        • Lamb D.S.
        • et al.
        Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
        Lancet Oncol. 2011; 12: 451-459
        • Stock R.G.
        • Stone N.N.
        • Kao J.
        • et al.
        The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
        Cancer. 2000; 89: 1829-1834
        • Akakura K.
        • Suzuki H.
        • Ichikawa T.
        • et al.
        A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
        Jpn J Clin Oncol. 2006; 36: 789-793
        • Gontero P.
        • Marchioro G.
        • Pisani R.
        • et al.
        Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study.
        Eur Urol. 2007; 51: 922-930
        • Chen M.K.
        • Luo Y.
        • Zhang H.
        • et al.
        Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non–extra node metastatic prostate cancer: 5-year experience in a single Chinese institution.
        J Cancer Res Clin Oncol. 2013; 139: 871-878
        • Peyromaure E.M.
        • Mao K.
        • Sun Y.
        • et al.
        A comparative study of prostate cancer detection and management in China and in France.
        Can J Urol. 2009; 16: 4472-4477
        • Oliveira I.S.
        • Pontes-Junior J.
        • Abe D.K.
        • et al.
        Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy.
        Int Braz J Urol. 2010; 36: 292-299
        • Gao X.
        • Qiu J.G.
        • Cai Y.B.
        • et al.
        Laparoscopic radical prostatectomy.
        Chin Med J (Engl). 2004; 117: 148-149
        • Cooperberg M.R.
        • Hilton J.F.
        • Carroll P.R.
        The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy.
        Cancer. 2011; 117: 5039-5046
        • Heidenreich A.
        • Varga Z.
        • Von Knobloch R.
        Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
        J Urol. 2002; 167: 1681-1686
        • Gao X.
        • Wang K.B.
        • Pu X.Y.
        • et al.
        Modified apical dissection of the prostate improves early continence in laparoscopic radical prostatectomy: technique and initial results.
        J Cancer Res Clin Oncol. 2010; 136: 511-516
        • Van Poppel H.
        • Vekemans K.
        • Da P.L.
        • et al.
        Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).
        Eur J Cancer. 2006; 42: 1062-1067
        • Meeks J.J.
        • Zhao L.
        • Greco K.A.
        • et al.
        Impact of prostate median lobe anatomy on robotic-assisted laparoscopic prostatectomy.
        Urology. 2009; 73: 323-327
        • Yang Y.
        • Luo Y.
        • Hou G.L.
        • et al.
        Laparoscopic radical prostatectomy after previous transurethral resection of the prostate in clinical T1a and T1b prostate cancer: a matched-pair analysis.
        Urol J. 2015; 12: 2154-2159
        • Bolla M.
        • Collette L.
        • Blank L.
        • et al.
        Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
        Lancet. 2002; 360: 103-106
        • Warde P.
        • Mason M.
        • Ding K.
        • et al.
        Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
        Lancet. 2011; 378: 2104-2111
        • Crook J.M.
        • Perry G.A.
        • Robertson S.
        • et al.
        Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients.
        Urology. 1995; 45: 624-632
        • Gerber G.S.
        • Thisted R.A.
        • Chodak G.W.
        • et al.
        Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis.
        Eur Urol. 1997; 32: 385-390
        • Ward J.F.
        • Zincke H.
        Radical prostatectomy for the patient with locally advanced prostate cancer.
        Curr Urol Rep. 2003; 4: 196-204
        • Casey J.T.
        • Meeks J.J.
        • Greco K.A.
        • et al.
        Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy.
        J Endourol. 2009; 23: 1519-1522
        • Ficarra V.
        • Cavalleri S.
        • Novara G.
        • et al.
        Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review.
        Eur Urol. 2007; 51: 45-56
        • Herrmann T.R.
        • Rabenalt R.
        • Stolzenburg J.U.
        • et al.
        Oncological and functional results of open, robot-assisted and laparoscopic radical prostatectomy: does surgical approach and surgical experience matter?.
        World J Urol. 2007; 25: 149-160
        • Hruza M.
        • Bermejo J.L.
        • Flinspach B.
        • et al.
        Long-term oncological outcomes after laparoscopic radical prostatectomy.
        BJU Int. 2013; 111: 271-280
        • Aus G.
        • Abbou C.C.
        • Bolla M.
        • et al.
        EAU guidelines on prostate cancer.
        Eur Urol. 2005; 48: 546-551
        • Karakiewicz P.I.
        • Hutterer G.C.
        Predictive models and prostate cancer.
        Nat Clin Pract Urol. 2008; 5: 82-92
        • Quinn D.I.
        • Henshall S.M.
        • Haynes A.M.
        • et al.
        Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models.
        J Clin Oncol. 2001; 19: 3692-3705
        • Fujioka T.
        • Koike H.
        • Aoki H.
        • et al.
        Significance of staging pelvic lymphadenectomy for prostatic cancer.
        Urol Int. 1987; 42: 380-384
        • Briganti A.
        • Chun F.K.
        • Salonia A.
        • et al.
        Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
        BJU Int. 2006; 98: 788-793
        • Schumacher M.C.
        • Burkhard F.C.
        • Thalmann G.N.
        • et al.
        Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?.
        Eur Urol. 2006; 50: 272-279
        • Van Baelen A.
        • Mottet N.
        • Spahn M.
        • et al.
        Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer.
        Adv Urol. 2012; 2012: 983058
        • Ouzzane A.
        • Rozet F.
        • Salas R.S.
        • et al.
        Positive surgical margins after minimally invasive radical prostatectomy in patients with pT2 and pT3a disease could be considered pathological upstaging.
        BJU Int. 2014; 113: 586-591
        • Studer U.E.
        • Whelan P.
        • Wimpissinger F.
        • et al.
        Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
        Eur Urol. 2014; 66: 829-838

      CHORUS Manuscript

      View Open Manuscript